University of Ottawa Heart Institute-led Study to Evaluate Novel Coronary Artery Disease Detection Device

Jan 21, 2020 | Cardiovascular, Coronary Artery Disease, Detection, Diagnostic, Heart Disease

University of Ottawa Heart Institute-led Study to Evaluate Novel Coronary Artery Disease Detection Device

Of nearly 375 North American applicants, Dr. Benjamin Chow, a clinical investigator, secured $1 million in funding as part of a seven-minute pitch for his groundbreaking research addressing the need for superior ways to detect coronary artery disease (CAD). Representing University of Ottawa Heart Institute, (UOHI) the investigational detection device is called CAD-det. If it works, it will offer greater preventative healthcare options for many thousands of people in under-serviced and remote areas. Chow, UOHI, and sponsor AusculSciences Canada, Inc. seek to address a leading cause of death and disability worldwide.

TD Ready Challenge Grant

The clinical cardiologist and clinical investigator from the University of Ottawa Heart Institute (UOHI) participated in the TD Ready Challenge in pursuit of the $1 million prize. Upon winning, Dr. Chow felt “humbled, flattered and excited to be the recipient,” reported YOUAREUNLTD. With the funding in hand—and a match from partner and industry sponsor AusculSciences Canada, Chow will seek to help not just his immediate patients but many more.

The Health Crisis: Coronary Artery Disease (CAD)

CAD is the leading cause of premature death worldwide, accounting for more deaths than all cancers combined reports the industry sponsor AusculSciences Canada. CAD is predicted to increase 18% by 2030 due to patient obesity, lifestyle stress factors and aging populations.

The Innovative Research: The CAD-det test

Now with $1 million to work with, Chow can commence his innovative research intended to help medical professionals identify earlier on coronary artery disease (CAD). He will lead a study aimed at validating a new, non-invasive, five-minute test for detecting CAD.  

Chow’s research at UOHI reveals that the CAD-det test (known as the CAD-det System) could be superior test as compared to current approaches, such as the exercise stress test (EST), while also representing a safer and more patient-friendly approach. It could be applied via telemedicine, potentially aiding many underserved patient populations with insufficient access to medical facilities with advanced diagnostic capabilities. The CAD-det has been designed via a collaboration of UOHI and AusculSciences Canada Inc. as a way to “revolutionize the standard of care for coronary artery disease (CAD) detection.”

According to AusculSciences Canada, the CAD-det System is a rapid, functional test designed to aid in the diagnosis of CAD by detecting the sounds associated with the turbulent blood flow in stenosed coronary arteries. In just a few minutes, the CAD-det System uses its patented technology to acquire and analyze cardiac acoustic data, and deliver results in real-time with high diagnostic accuracy. The test is completely non-invasive and doesn’t expose the patient to stress or ionizing radiation. The product can be used to assist in clinical decision making, with high diagnostic accuracy—and ensure that advanced imaging diagnostics are reserved for higher-risk patients, thereby reducing healthcare costs and improving patient safety according to the industry sponsor AusculSciences Canada.

The Study

Chow and UOHI embark now to develop and implement a multi-center study of the CAD-det test, reports YOUAREUNLTD. Chow will involve multiple research sites in Canada with a keen understanding that a diverse patient population is required for participation. With a target of 1,600 participating patients, the study team will conduct a statistical analysis under independent data review panel to determine and assess the CAD-det’ performance and results. Chow seeks to demonstrate that the CAD-det is superior to EST in terms of “clinical accuracy, patient safety, patient preference and cost effectiveness per diagnosis aiding in in the adoption of this game-changing technology to benefit patients through the earlier and better detection of CAD within Canada and throughout the world.”

Study Sponsor & Collaborators

Study sponsor AusculSciences Canada Inc. has collaborated with UOHI to develop the CAD-det technology. They will support the study and will match the $1 million from the TD Ready Challenge grant with in-kind contributions, such as CAD-det units, test consumables, data management software tools, clinical monitoring personnel costs, and required travel for clinical monitoring visits.

AusculSciences Canada is a small, privately held company in Canada. They employ under 25 and maintain a licensing agreement with UOHI for the underlying CAD-det IP. If the market takes off for this product, they could be on to something valuable.

Collaborators include UOHIHorizon Health NetworkUniversity of Calgary, and Hamilton Health Sciences Corporation

Clinical Investigational Sites

The following clinical investigational sites will support this study. In Calgary, the Foothills Medical Centre will be led by Principal Investigator (PI) Todd Anderson, MD. While in New Brunswick Horizon Health Network’s, Sohrab Lutchmedial, MD, FRCP, will serve as PI. McMaster University will participate led by Richard Whitlock, MD as PI, while in Ontario, of course the PI will be UOHI’s Dr. Benjamin Chow

Lead Research/Investigator

Dr. Benjamin Chow, University of Ottawa Heart Institute

Call to Action: Interested in this study? We link to, or you may contact TrialSite News if you need support or insight. Interested in doing business with AusculSciences Canada? Contact them.



Pin It on Pinterest